Essex Bio-Technology (HKG:1061) said the anti-VEGF ophthalmic injection bio-pharmaceutical product, HLX04-O, co-developed by two of its subsidiaries and Shanghai Henlius Biotech (HKG:2696), saw the last visit of the last patient (LPLV) for its phase 3 clinical study.
The study is a randomized, double-blinded, active-controlled, and global study conducted in patients with exudative age-related macular degeneration or wet-AMD, a Monday Hong Kong bourse filing said.
The drug is a new ophthalmic preparation product and is planned to be used for the treatment of wet-AMD in China.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.